Ravulizumab-cwvz (Ultomiris®)
IMPORTANT REMINDER
We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the Medical Policy and a health plan or government program (e.g., TennCare), the express terms of the health plan or government program will govern.
POLICY
I. INDICATIONS
The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.
FDA-Approved Indications
1. Ultomiris is indicated for the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH).
2. Ultomiris is indicated for the treatment of adults and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).
3. Ultomiris is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.
Limitations of Use: Ultomiris is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).
All other indications are considered experimental/investigational and not medically necessary.
II. DOCUMENTATION
Submission of the following information is necessary to initiate the prior authorization review for new requests for treatment of:
A. For initial requests:
1. Paroxysmal nocturnal hemoglobinuria: flow cytometry used to show results of glycosylphosphatidylinositol-anchored proteins (GPI-APs) deficiency
2. Atypical hemolytic uremic syndrome: ADAMTS 13 level
3. Generalized myasthenia gravis: anti-acetylcholine receptor (AchR) antibody positive, clinical classification of myasthenia gravis score, MG activities of daily living score, use of IVIG, use of two immunosuppressive therapies
B. For continuation requests: Chart notes or medical record documentation supporting positive clinical response.
III. CRITERIA FOR INITIAL APPROVAL
A. Paroxysmal nocturnal hemoglobinuria
Authorization of 6 months may be granted for treatment of paroxysmal nocturnal hemoglobinuria (PNH) when all of the following criteria are met:
1. The diagnosis of PNH was confirmed by detecting a deficiency of glycosylphosphatidylinositol-anchored proteins (GPI-APs) as demonstrated by either of the following:
a. At least 5% PNH cells
b. At least 51% of GPI-AP deficient poly-morphonuclear cells
2. Flow cytometry is used to demonstrate GPI-APs deficiency
B. Atypical hemolytic uremic syndrome (aHUS)
Authorization of 6 months may be granted for treatment of atypical hemolytic uremic syndrome (aHUS) not caused by Shiga toxin when all of the following criteria are met:
1. Absence of Shiga toxin
2. ADAMTS 13 activity level above 5%
C. Generalized myasthenia gravis (gMG)
Authorization of 6 months may be granted for treatment of generalized myasthenia gravis (gMG) when all of the following criteria are met:
1. Anti-acetylcholine receptor (AchR) antibody positive
2. Myasthenia Gravis Foundation of America (MGFA) clinical classification II to IV
3. MG activities of daily living (MG-ADL) total score ≥6
4. Meets both of the following:
a. Member has had an inadequate response to at least two immunosuppressive therapies listed below:
i. azathioprine
ii. cyclosporine
iii. mycophenolate mofetil
iv. tacrolimus
v. methotrexate
vi. cyclophosphamide
vii. rituximab
b. Member has inadequate response to chronic IVIG
IV. CONTINUATION OF THERAPY
A. Paroxysmal nocturnal hemoglobinuria
Authorization of 12 months may be granted for continued treatment in members requesting reauthorization when there is no evidence of unacceptable toxicity or disease progression while on the current regimen and demonstrate a positive response to therapy (e.g., improvement in hemoglobin levels, normalization of lactate dehydrogenase [LDH] levels).
B. Atypical hemolytic uremic syndrome (aHUS)
Authorization of 12 months may be granted for continued treatment in members requesting reauthorization when there is no evidence of unacceptable toxicity or disease progression while on the current regimen and demonstrate a positive response to therapy (e.g., normalization of lactate dehydrogenase (LDH) levels, platelet counts).
C. Generalized myasthenia gravis (gMG)
Authorization of 12 months may be granted for continued treatment in members requesting reauthorization when there is no evidence of unacceptable toxicity or disease progression while on the current regimen and member demonstrates a positive response to therapy (e.g., improvement in MG-ADL score, changes compared to baseline in Quantitative Myasthenia Gravis (QMG) total score).
V. DOSAGE AND ADMINISTRATION
Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.
MEDICATION QUANTITY LIMITS
Drug Name |
Diagnosis |
Maximum Dosing Regimen |
Ultomiris (Ravulizumab) |
Atypical Hemolytic Uremic Syndrome (aHUS) |
Route of Administration: Intravenous ≥1 month(s) 5-9kg: Initial: 600mg once Maintenance: 300mg every 4 weeks, starting 2 weeks after loading dose 10-19kg: Initial: 600mg once Maintenance: 600mg every 4 weeks, starting 2 weeks after loading dose 20-29kg: Initial: 900mg once Maintenance: 2100mg every 8 weeks, starting 2 weeks after loading dose 30-39kg: Initial: 1200mg once Maintenance: 2700mg every 8 weeks, starting 2 weeks after loading dose 40-59kg: Initial: 2400mg once Maintenance: 3000mg every 8 weeks, starting 2 weeks after loading dose 60-99kg: Initial: 2700mg once Maintenance: 3300mg every 8 weeks, starting 2 weeks after loading dose >100kg: Initial: 3000mg once Maintenance: 3600mg every 8 weeks, starting 2 weeks after loading dose |
Ultomiris (Ravulizumab) |
Generalized Myasthenia Gravis (gMG) |
Route of Administration: Intravenous ≥18 year(s) 40-59kg Initial: 2400mg once Maintenance: 3000mg every 8 weeks, starting 2 weeks after loading dose 60-99kg Initial: 2700mg once Maintenance: 3300mg every 8 weeks, starting 2 weeks after loading dose >100kg Initial:3000mg once Maintenance: 3600mg every 8 weeks, starting 2 weeks after loading dose |
Ultomiris (Ravulizumab) |
Neuromyelitis Optica Spectrum Disorder (NMOSD) |
Route of Administration: Intravenous ≥18 year(s) 40-59kg Initial: 2400mg once Maintenance: 3000mg every 8 weeks, starting 2 weeks after loading dose 60-99kg Initial: 2700mg once Maintenance: 3300mg every 8 weeks, starting 2 weeks after loading dose >100kg Initial: 3000mg once Maintenance: 3600mg every 8 weeks, starting 2 weeks after loading dose |
Ultomiris (Ravulizumab) |
Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Route of Administration: Intravenous ≥1 month(s) 5-9kg Initial: 600mg once Maintenance: 300mg every 4 weeks, starting 2 weeks after loading dose 10-19kg Initial: 600mg once Maintenance: 600mg every 4 weeks, starting 2 weeks after loading dose 20-29kg Initial: 900mg once Maintenance: 2100mg every 8 weeks, starting 2 weeks after loading dose 30-39kg Initial: 1200mg once Maintenance: 2700mg every 8 weeks, starting 2 weeks after loading dose 40-59kg Initial: 2400mg once Maintenance: 3000mg every 8 weeks, starting 2 weeks after loading dose 60-99kg Initial: 2700mg once Maintenance: 3300mg every 8 weeks, starting 2 weeks after loading dose >100kg Initial: 3000mg once Maintenance: 3600mg every 8 weeks, starting 2 weeks after loading dose
|
APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS
BlueCross BlueShield of Tennessee’s Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.
ADDITIONAL INFORMATION
For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).
REFERENCES
1. Ultomiris [package insert]. Boston, MA: Alexion Pharmaceuticals, Inc.; July 2022.
2. Parker CJ. Management of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitory therapy. Hematology. 2011; 21-29.
3. Lee JW, Sicre de Fontbrune F, Wong LL, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: The 301 study. Blood. 2018 Dec 3; pii: blood-2018-09-876136.
4. Borowitz MJ, Craig F, DiGiuseppe JA, et al. Guidelines for the Diagnosis and Monitoring of Paroxysmal Nocturnal Hemoglobinuria and Related Disorders by Flow Cytometry. Cytometry B Clin Cytom. 2010: 78: 211-230.
5. Preis M, Lowrey CH. Laboratory tests for paroxysmal nocturnal hemoglobinuria (PNH). Am J Hematol. 2014;89(3):339-341.
6. Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. Published online: April 11, 2015.
7. Parker CJ. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. Hematology Am Soc Hematol Educ Program. 2016;2016(1):208-216.
8. Sanders D, Wolfe G, Benatar M et al. International consensus guidance for management of myasthenia gravis. Neurology. 2021; 96 (3) 114-122.
9. Tuan Vu, Andreas Meisel, Renato Mantegazza, et al. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. NEJM Evid 2022; 1 (5)
10. Dezern AE, Borowitz MJ. ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 1 - clinical utility. Cytometry B Clin Cytom. 2018 Jan;94(1):16-22.
ORIGINAL EFFECTIVE DATE: 5/31/2019
MOST RECENT REVIEW DATE: 7/9/2024
ID_CHS
Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.
This document has been classified as public information